Ribostamycin production by a mutant of butirosin producing bacteria.
By the use of our improved colony selection technique, xylostasin and ribostamycin producing mutants were isolated from nitrosoguanidine treated Bacillus circulans B15M, a producer of butirosins A and B. Among these structurally related aminoglycosides, ribostamycin is the well-known product of a Steptomyces and has not been isolated as a bacterial metabolite. A selected mutant of strain 306, which produces xylostasin and ribostamycin, was futher mutagenized in expectation of getting an improved strain having the ability to accumulate a large amount of ribostamycin in the culture broth. One mutant, strain 451, derived from strain 306, produced ribostamycin free of xylostasin.
D000900:Anti-Bacterial Agents / Q000096:biosynthesis*; D001407:Bacillus / Q000378:metabolism*; D001419:Bacteria / Q000187:drug effects; D002076:Butirosin Sulfate / Q000096:biosynthesis*; D002855:Chromatography, Thin Layer; D005285:Fermentation; D008826:Microbial Sensitivity Tests; D009154:Mutation; D012271:Ribostamycin / Q000096:biosynthesis* / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D012271:Ribostamycin; D002076:Butirosin Sulfate